Neflamapimod Improves Episodic Memory in Early Alzheimer’s Patients in Phase 2a Trial

Neflamapimod Improves Episodic Memory in Early Alzheimer’s Patients in Phase 2a Trial
Investigational therapy Neflamapimod led to significant improvements in episodic memory function in patients with early Alzheimer's disease, results from EIP Pharma's Phase 2a clinical trial show. "Significant unmet need exists for improved Alzheimer's treatments which is why we are so encouraged by these data demonstrating neflamapimod's potential to improve memory function in patients with Alzheimer's disease," John Alam, MD, EIP Pharma’s CEO, said in a
Subscribe or to access all post and page content.